Evolution of Two Amino Acid Positions Governing Broad Neutralization Resistance in a Strain of Feline Immunodeficiency Virus over 7 Years of Persistence in Cats

Clinical and Diagnostic Laboratory Immunology

Volumn 10, Issue 6, 2003, Pages 1109-1116

  Pistello, Mauro ^a   Matteucci, Donatella ^a   Giannecchini, Simone ^a   Bonci, Francesca ^a   Sichi, Olimpia ^a   Presciuttini, Silvano ^a   Bendinelli, Mauro ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAT; CONTROLLED STUDY; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, VIRAL; CATS; DRUG RESISTANCE; EVOLUTION, MOLECULAR; IMMUNODEFICIENCY VIRUS, FELINE; LENTIVIRUS INFECTIONS; NEUTRALIZATION TESTS; TIME FACTORS; VIRAL STRUCTURAL PROTEINS;

EID: 0344394184     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.10.6.1109-1116.2003     Document Type: Article

References (34)

1. Bandelt, H.-J., P. Forster, and A. Röhl. 1999. Median-joining networks for inferring intraspecific phylogenies. Mol. Biol. Evol. 16:37-48.
2. Beaumont, T., A. van Nuenen, S. Broersen, W. A. Blattner, V. V. Lukashov, and H. Schuitemaker. 2001. Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J. Virol. 75:2246-2252.
3. Bendinelli, M., M. Pistello, D. Del Mauro, G. Cammarota, F. Maggi, A. Leonildi, S. Giannecchini, C. Bergamini, and D. Matteucci. 2001. During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein. J. Virol. 75:4584-4593.
4. Burton, D. R., and P. W. Parren. 2000. Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection? Nat. Med. 6:123-125.
5. Burton, D. R., E. O. Saphire, and P. W. Parren. 2001. A model for neutralization of viruses based on antibody coating of the virion surface. Curr. Top. Microbiol. Immunol. 260:109-143.
6. Cammarota, G., D. Matteucci, M. Pistello, E. Nicoletti, S. Giannecchini, and M. Bendinelli. 1996. Reduced sensitivity to strain-specific neutralization of laboratory-adapted feline immunodeficiency virus after one passage in vivo: association with amino acid substitutions in the V4 region of the surface glycoprotein. AIDS Res. Hum. Retrovir. 12:173-175.
7. Cayabyab, M., G. B. Karlsson, B. A. Etemad-Moghadam, W. Hofmann, T. Steenbeke, M. Halloran, J. W. Fanton, M. K. Axthelm, N. L. Letvin, and J. G. Sodroski. 1999. Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2). J. Virol. 73:976-984.
8. Elder, J. H., and T. R. Phillips. 1995. Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections. Adv. Virus Res. 45:225-247.
9. Giannecchini, S., D. Matteucci, and M. Bendinelli. 1998. Effect of enzymatic deglycosylation on feline immunodeficiency virus sensitivity to antibody-mediated neutralization. AIDS Res. Hum. Retrovir. 14:199-204.
10. Giannecchini, S., D. Matteucci, A. Ferrari, M. Pistello, and M. Bendinelli. 2001. Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro. J. Virol. 75:8868-8873.
11. Hall, T. A. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 41:95-98.
12. Hofman-Lehmann, R., J. Vlasak, A.-L. Chenine, P.-L. Li, T. W. Baba, D. C. Montefiori, H. M. McClure, D. C. Anderson, and R. M. Ruprecht. 2002. Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage. J. Virol. 76:5278-5284.
13. Hosie, M. J., B. J. Willett, D. Klein, T. H. Dunsford, C. Cannon, M. Shimojiama, J. C. Neil, and O. Jarrett. 2002. Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence. J. Virol. 76:6062-6072.
14. Johnson, W. E., J. Morgan, J. Reitter, B. A. Puffer, S. Czajak, R. W. Doms, and R. C. Desrosiers. 2002. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J. Virol. 76:2075-2086.
15. Kwong, P. D., M. L. Doyle, D. J. Casper, C. Cicala, S. A. Leavitt, S. Majeed, T. D. Steenbeke, M. Venturi, I. Chaiken, M. Fung, H. Katinger, P. W. H. I. Parren, J. Robinson, D. Van Ryk, L. Wang, D. R. Burton, E. Freire, R. Wyatt, J. Sodroski, W. A. Hendrickson, and J. Arthos. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678-682.
16. Labrijn, A. F., and P. W. H. I. Parren. 1999. Neutralizing epitopes of HIV-1, p. 18-34. In B. Korber, C. Brander. B. F. Haynes, J. P. Moore, R. Koup, B. Walker, and D. I. Watkins (ed.), HIV molecular immunology database. Los Alamos National Laboratory, Los Alamos, N.M.
17. Lerner, D. L., and J. H. Elder. 2000. Expanded host cell tropism and cytopathic properties of feline immunodeficiency virus strain PPR subsequent to passage through interleukin-2-independent T cells. J. Virol. 74:1854-1863.
18. Loveday, C. 2001. Nucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26:S10-S24.
19. Maldarelli, F. 2003. HIV-1 fitness and replication capacity: what are they and can they help in patient management? Curr. Infect. Dis. Rep. 5:77-84.
20. Matteucci, D., P. Mazzetti, F. Baldinotti, L. Zaccaro, C. Giannelli, and M. Bendinelli. 1995. The feline lymphoid cell line MBM and its use for feline immunodeficiency virus isolation and quantitation. Vet. Immunol. Immunopathol. 46:71-82.
21. Miller, V. 2001. Resistance to protease inhibitors. J. Acquir. Immune Defic. Syndr. 26:S34-S50.
22. Nicholas, K. B., H. B. Nicholas, Jr., and D. W. Deerfield II. 1997. GeneDoc: analysis and visualization of genetic variation. EMBNEW News 4:14.
23. Park, E. J., M. K. Gorny, S. Zolla-Pazner, and J. V. Quinnan, Jr. 2000. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J. Virol. 74:4183-4191.
24. Park, E. J., and G. V. Quinnan, Jr. 1999. Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. J. Virol. 73:5707-5713.
25. Parren, P. W. H. I., J. P. Moore, D. R. Burton, and Q. J. Sattentau. 1999. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13:S137-S162.
26. Pedersen, N. C. 1993. Feline immunodeficiency virus infection, p. 181-228. In J. A. Levy (ed.), The retroviridae, vol. 2. Plenum Press, New York, N.Y.
27. Pedersen, N. C., E. W. Ho, M. L. Brown, and J. K. Yamamoto. 1987. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235:790-793.
28. Thompson, J. D., T. J. Gibson, F. Plewniak, F. Jeanmougin, and D. G. Higgins. 1997. The ClustalX Windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 24:4876-4882.
29. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, N. L. Komarova, M. A. Nowak, B. H. Hahn, P. D. Kwong, and G. M. Shaw. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
30. Willett, B. J., J. N. Flynn, and M. J. Hosie. 1997. FIV infection of the domestic cat: an animal model for AIDS. Immunol. Today 18:182-189.
31. Xia, X. 2000. Data analysis in molecular biology and evolution. Kluwer Academic Publishers, Boston, Mass.
32. Xiao, Y., X. Dong, and Y. H. Chen. 2002. Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1. Immunol. Res. 25:193-200.
33. Yamamoto, J. K., C. D. Ackley, H. Zochlinski, H. Louie, E. Pembroke, M. Torten, H. Hansen, R. Munn, and T. Okuda. 1991. Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines. Intervirology 32:361-375.
34. York, J., K. E. Follis, M. Trahey, P. N. Nyambi, S. Zolla-Pazner, and J. H. Nunberg. 2001. Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1. J. Virol. 75:2741-2752.